WallStreetZenWallStreetZen

NASDAQ: AVTX
Avalo Therapeutics Inc Stock

$12.51-0.47 (-3.62%)
Updated Jul 18, 2024
AVTX Price
$12.51
Fair Value Price
-$0.86
Market Cap
$12.94M
52 Week Low
$3.95
52 Week High
$77.57
P/E
-0.06x
P/B
-0.11x
P/S
15.51x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.45M
Earnings
-$142.88M
Gross Margin
54.9%
Operating Margin
-9,682.62%
Profit Margin
-9,853.7%
Debt to Equity
-2
Operating Cash Flow
-$27M
Beta
1.2
Next Earnings
Aug 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A

AVTX Overview

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AVTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AVTX ($12.51) is overvalued by 1,550.17% relative to our estimate of its Fair Value price of -$0.86 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AVTX ($12.51) is not significantly undervalued (1,550.17%) relative to our estimate of its Fair Value price of -$0.86 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AVTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AVTX due diligence checks available for Premium users.

Be the first to know about important AVTX news, forecast changes, insider trades & much more!

AVTX News

Valuation

AVTX fair value

Fair Value of AVTX stock based on Discounted Cash Flow (DCF)
Price
$12.51
Fair Value
-$0.86
Undervalued by
1,550.17%
AVTX ($12.51) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AVTX ($12.51) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AVTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AVTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.06x
Industry
-26.99x
Market
29.86x

AVTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-0.11x
Industry
6.19x

AVTX's financial health

Profit margin

Revenue
$0.0
Net Income
-$121.3M
Profit Margin
0%
AVTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AVTX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$123.7M
Liabilities
$224.8M
Debt to equity
-2
AVTX's short-term liabilities ($215.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVTX's short-term assets ($111.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AVTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.2M
Investing
$356.0k
Financing
$108.6M
AVTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AVTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
AVTX$12.94M-3.63%-0.06x-0.11x
MNPR$12.59M+1.41%-1.38x1.68x
IMNN$13.49M-1.03%-0.71x1.59x
VCNX$12.25M+14.52%-0.28x4.61x
CDIO$12.02M-2.93%-0.71x3.96x

Avalo Therapeutics Stock FAQ

What is Avalo Therapeutics's quote symbol?

(NASDAQ: AVTX) Avalo Therapeutics trades on the NASDAQ under the ticker symbol AVTX. Avalo Therapeutics stock quotes can also be displayed as NASDAQ: AVTX.

If you're new to stock investing, here's how to buy Avalo Therapeutics stock.

What is the 52 week high and low for Avalo Therapeutics (NASDAQ: AVTX)?

(NASDAQ: AVTX) Avalo Therapeutics's 52-week high was $77.57, and its 52-week low was $3.95. It is currently -83.87% from its 52-week high and 216.71% from its 52-week low.

How much is Avalo Therapeutics stock worth today?

(NASDAQ: AVTX) Avalo Therapeutics currently has 1,034,130 outstanding shares. With Avalo Therapeutics stock trading at $12.51 per share, the total value of Avalo Therapeutics stock (market capitalization) is $12.94M.

Avalo Therapeutics stock was originally listed at a price of $11,520.05 in Nov 13, 2015. If you had invested in Avalo Therapeutics stock at $11,520.05, your return over the last 8 years would have been -99.89%, for an annualized return of -57.39% (not including any dividends or dividend reinvestments).

How much is Avalo Therapeutics's stock price per share?

(NASDAQ: AVTX) Avalo Therapeutics stock price per share is $12.51 today (as of Jul 18, 2024).

What is Avalo Therapeutics's Market Cap?

(NASDAQ: AVTX) Avalo Therapeutics's market cap is $12.94M, as of Jul 19, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Avalo Therapeutics's market cap is calculated by multiplying AVTX's current stock price of $12.51 by AVTX's total outstanding shares of 1,034,130.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.